ascopubs.org

Pharmacokinetic–pharmacodynamic (PK-PD) modeling and simulation of serdemetan-induced QTc effects in a first-in-human study.

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
PharmTech

Overcoming PK/PD Modeling Challenges

PK/PD modeling is essential for understanding ADMET properties, optimizing dosing regimens, and reducing late-stage attrition rates in drug development. AI/ML algorithms enhance PK/PD modeling by ...
ascopubs.org

Modeling of pharmacodynamic (PD) biomarkers (BM) related to CDK4/6 inhibition and exploratory BM-response (progression free survival [PFS]) analyses in patients with advanced ...

Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR. This is an ASCO Meeting Abstract ...
Pharmabiz

Certara introduces PK/PD modelling & simulation software, Phoenix 8.2 for drug development

Certara, the global model-informed drug development and decision support leader, announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) modelling ...
Pharmabiz

Certara introduces version 8.1 of industry-leading Phoenix PK/PD modelling & simulation software

Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, announced the launch of Phoenix 8.1. Phoenix is the most advanced and ...